Antimicrobial resistance in Staphylococcus aureus

被引：31

作者：

Smith, TL ^{[1
]}

Jarvis, WR ^{[1
]}

机构：

[1] Ctr Dis Control & Prevent, Hosp Infect Program, Natl Ctr Infect Dis, Atlanta, GA 30333 USA

来源：

MICROBES AND INFECTION | 1999年 / 1卷 / 10期

关键词：

Staphylococcus aureus; antimicrobials; resistance;

D O I：

10.1016/S1286-4579(99)80082-3

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Recognized since 1883 as a common cause of infection, Staphylococcus aureus' preantimicrobial-era bacteremia mortality rate was 82%. The mortality of that era threatens to return as evidence of growing vancomycin resistance undermines the utility of vancomycin therapy. Successful treatment of S. aureus infections requires knowledge of its antimicrobial resistance capacity. (C) Elsevier, Paris.

引用

页码：795 / 805

页数：11

共 101 条

[61] Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics [J].

Medeiros, AA .

CLINICAL INFECTIOUS DISEASES, 1997, 24 :S19-S45

[62] ENTEROCOCCI RESISTANT TO MULTIPLE ANTIMICROBIAL AGENTS, INCLUDING VANCOMYCIN - ESTABLISHMENT OF ENDEMICITY IN A UNIVERSITY MEDICAL-CENTER [J].

MORRIS, JG ;

SHAY, DK ;

HEBDEN, JN ;

MCCARTER, RJ ;

PERDUE, BE ;

JARVIS, W ;

JOHNSON, JA ;

DOWLING, TC ;

POLISH, LB ;

SCHWALBE, RS .

ANNALS OF INTERNAL MEDICINE, 1995, 123 (04) :250-259

[63] In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis [J].

Mulazimoglu, L ;

Drenning, SD ;

Yu, VL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2428-2430

[64] THE CRISIS IN ANTIBIOTIC-RESISTANCE [J].

NEU, HC .

SCIENCE, 1992, 257 (5073) :1064-1073

[65] Quinolone resistance mutations in topoisomerase IV: Relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus [J].

Ng, EY ;

Trucksis, M ;

Hooper, DC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1881-1888

[66]

NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P196

[67]

OGSTON A, 1883, J ANAL PHYSL, V17, P24

[68]

PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582

[69] First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital [J].

Ploy, MC ;

Grélaud, C ;

Martin, C ;

de Lumley, L ;

Denis, F .

LANCET, 1998, 351 (9110) :1212-1212

[70] In vitro activities of co-amoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroresistant Staphylococcus aureus:: A controlled study with vancomycin [J].

Prieto, J ;

Aguilar, L ;

Giménez, MJ ;

Toro, D ;

Gómez-Lus, ML ;

Dal-Ré, R ;

Balcabao, IP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (07) :1574-1577

← 2 3 4 5 6 7 8 9 10 11 →